Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Rituximab-refractory Follicular Lymphoma
Clinical trial NCT01275209 · COMPLETED
Trial details
- NCT number
- NCT01275209
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2011-02-01
- Primary completion
- 2012-05-01
- Enrollment
- 1
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.